Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 10/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1575508 | 0.96 | NMT1 (0.58) | NMT1ITGB3ITGA2BSLC6A4 | |
| SCHEMBL26666895 | 0.83 | GRM2 (0.46) | NMT1ITGB3ITGA2BHRH3SLC6A4 | |
| Hydrochloric Acid SCHEMBL26666890 | 0.82 | GRM2 (0.46) | NMT1ITGB3ITGA2BHRH3SLC6A4 | |
| SCHEMBL6011372 | 0.82 | CHRM1 (0.44) | NMT1 | |
| SCHEMBL3037834 | 0.81 | GBA1 (0.56) | NMT1SLC6A4 | |
| Hydrochloric Acid SCHEMBL6011621 | 0.81 | CHRM1 (0.43) | NMT1SLC6A4 | |
| Hydrochloric Acid SCHEMBL3034504 | 0.80 | GBA1 (0.54) | NMT1SLC6A4 | |
| SCHEMBL12204971 | 0.80 | GPR119 (0.59) | ITGB3ITGA2BSLC6A4 | |
| SCHEMBL5127443 | 0.80 | NMT1 (0.43) | NMT1HRH3 | |
| SCHEMBL11399497 | 0.80 | NMT1 (0.51) | NMT1ITGB3ITGA2BHRH3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46117-E1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-08-23 | — | — | US | disclosed |
| US-7417043-B2 | Modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2008-08-26 | — | — | US | disclosed |
| US-20060135531-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2006-06-22 | — | — | US | disclosed |
| EP-1240142-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2005-10-19 | — | — | EP | disclosed |
| US-6903120-B2 | A 4-(phenyl-N- alkyl)-piperidine derivatives for treatment of central nervous system disorders, Parkinson disease, anxiety, dyskinesias, dystonias, Tourette's disease, psychoses, hallucinoses, sleep disorder, autism | A. CARLSSON RESEARCH AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1428822-A2 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2003-07-24 | — | — | US | disclosed |
| EP-1240142-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046145-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135531-A1 | Modulators of dopamine neurotransmission | SLC6A3, BRS3, CHRNA3 | NMT1 4137/4885ITGB3 1745/4885ITGA2B 4378/4885 |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | NMT1 3296/4885ITGB3 1106/4885ITGA2B 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.